Daniel Long Sells 3,333 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,647,265.96. This represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Price Performance

Shares of NASDAQ SEPN opened at $36.75 on Friday. The stock has a market capitalization of $1.72 billion, a PE ratio of -68.06 and a beta of 2.30. Septerna, Inc. has a one year low of $13.67 and a one year high of $51.10. The business’s fifty day moving average price is $37.44 and its 200-day moving average price is $31.19.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. As a group, equities analysts expect that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on SEPN shares. Stifel Nicolaus set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. JonesTrading boosted their target price on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a report on Tuesday, August 11th. Finally, Truist Financial lifted their price target on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Septerna presently has a consensus rating of “Moderate Buy” and an average price target of $52.44.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently bought and sold shares of SEPN. Group One Trading LLC grew its position in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Septerna in the fourth quarter worth $35,000. Russell Investments Group Ltd. bought a new stake in Septerna during the third quarter valued at $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Septerna during the fourth quarter valued at $53,000. Finally, Balyasny Asset Management L.P. purchased a new position in Septerna during the fourth quarter worth about $100,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.